Extended trial tests daily pill to ease debilitating muscle locking
NCT ID NCT06549400
Summary
This study is following up on a previous trial to see how safe and helpful a daily medication called mexiletine is over a longer period for people with myotonic dystrophy types 1 and 2. It involves about 176 adults who have already finished the earlier study. Everyone in this new phase receives the active drug for 18 months to see if it continues to improve muscle stiffness, walking, and quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYOTONIC DYSTROPHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aarhus University Hospital
Aarhus, Denmark
-
Azienda Ospedaliera Universitaria Policlinico Tor Vergata
Rome, Italy
-
Laboratory for Muscle Diseases and Neuropathies
Leuven, Belgium
-
Ludug-Maximilians University
München, Germany
-
University College Hospital
London, United Kingdom
-
University Hospital of Madrid
Madrid, Spain
Conditions
Explore the condition pages connected to this study.